bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: D N O S A J J M A M F J
2018: D

 
  Other news for:
Lymphoma
 Resources from HONselect
Chemoimmunotherapy Regimen Approved to Treat DLBCL

TUESDAY, June 11, 2019 (HealthDay News) -- Polivy (polatuzumab vedotin-piiq), a novel antibody-drug conjugate, received approval to treat patients with diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab, the U.S. Food and Drug Administration announced today. The combination was approved for patients whose disease has progressed or returned after at least two previous therapies.

Approval was based on a study of 80 patients with relapsed or refractory DLBCL randomly assigned to receive either Polivy with bendamustine and rituximab or bendamustine and rituximab alone. Researchers found a complete response rate of 40 percent with Polivy plus bendamustine and rituximab compared with 18 percent with bendamustine and rituximab alone. Twenty-five patients achieved a partial or complete response with Polivy plus bendamustine and rituximab; 64 percent of these patients had a duration of response of six months or longer and 48 percent achieved a duration of response of at least one year.

The most commonly reported side effects of the combination of Polivy plus bendamustine and rituximab included neutropenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, fever, decreased appetite, and pneumonia.

Patients should be closely monitored for infusion-related reactions, low blood counts, fatal or serious infections, tumor lysis syndrome, hepatotoxicity, and progressive multifocal leukoencephalopathy. The FDA noted that women of reproductive age should be advised to use effective contraception during treatment and for three months following the last dose, and those who are pregnant or breastfeeding should not be treated with Polivy.

Approval of Polivy was granted to Genentech.

More Information

Health News Copyright © 2019 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=747332

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Lymphoma
Infection
Tumor Lysis Syndrome
Fever
Lymphoma, B-Cell
Thrombocytopenia
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact